Risks associated with parenteral treatment of acute agitation;Risico's van de parenterale behandeling van acute agitatie

Tijdschrift voor Psychiatrie

Volumn 48, Issue 2, 2006, Pages 135-139

  Boomsma, M M ^a,b   Mengels, O ^a   Van Olden, R W ^a  

^a Lilly Nederland ^*  (United States)

^b Lilly Nederland BV   (Netherlands)

Author keywords

Acute agitation; Parenteral therapy; Safety

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ACUTE DISEASE; AGITATED DEPRESSION; CARDIOTOXICITY; CRISIS INTERVENTION; DRUG FATALITY; HUMAN; HYPOTENSION; LARYNX SPASM; MEDICAL LITERATURE; MOTOR DYSFUNCTION; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION;

ANTIPSYCHOTIC AGENTS; EMERGENCY MEDICAL SERVICES; HUMANS; INFUSIONS, PARENTERAL; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISK FACTORS; SAFETY;

EID: 33244478518     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Addonizio, G., & Alexopoulos, G.S. (1988). Drug-induced dystonia in young and elderly patients. The American Journal of Psychiarry, 145, 869-871.
2. Barnes, C.W., Alderton, D., & Castle, D. (2002). The development of Clinical Guidelines for the use of Zuclopentixol Acetate. Australasian Psychiarry, 10, 54-58.
3. Casey, D.E. (1994). Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatrica Scandinavica (Suppl.), 380, 14-20.
4. College ter Beoordeling van Geneesmiddelen. (1998). Brief van Staatstoezicht op de Volksgezondheid, Inspectie voor de Gezondheidszorg aan alle arisen in Nederland over Sertindol (Serdolect). http://www.cbg-meb.nl
5. Currier, G.W., Allen, M.H., Bunney, E.B., e.a. (2004). Safety of medications used to treat acute agitation. The Journal of Emergency Medicine, 27(Suppl. 4), S19-S24.
6. European Medians Agency. (2005). Zyprexa. European Public Assessment Report. http://www.emea.eu.int/humandocs/Humans/EPAR/ zyprexa/zyprexa.htm
7. Food and Drug Administration. (2001). NDA 20-825 Approval Letter and Labeling. Attachment 1 Ziprasidone (Ziprasidone Hcl).http://www. fda.gov/cder/foi/label/2001/20825lbl.pdf
8. Fruncillo, R.J., Gibbons, W.J., Vlasses, P.H., e.a. (1985). Severe hypotension associated with concurrent clonidine and antipsychotic medication. The American Journal of Psychiatry, 142, 274.
9. Harten, P.N. van, Hoek, H.W., & Kahn, R.S. (1999). Acute dystonia induced by drug treatment. British Medical Journal, 319, 623-626.
10. Haverkamp, W., Breithardt, G., Camm, A.J., e.a. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Research, 47, 219-233.
11. Inspectie voot de Gezondheidszorg. (2004). Rapport Bopzis-3 info 2003/4. http://www.igz.nl/bestanden/Bopzis-3INFO2003nr4.pdf
12. King, D.J., Burke, M., & Lucas, R.A. (1995). Antipsychotic drug-induced dysphoria. The British Journal of Psychiatry, 167, 480-482.
13. Koek, R.J., & Pi, E.H. (1989). Acute laryngeal dystonic reactions to neuroleptics. Psychosomatic, 30, 359-364.
14. Levy, R.H. (1996). Sedation in acute and chronic agitation. Pharmacotherapy, 16, 152S-159S.
15. McAllister-Williams, R.H., & Ferrier, I.N. (2002). Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. The British Journal of Psychiatry, 180, 485-489.
16. Morganroth, J., Brozovich, F. V., McDonald, J.T., e.a. (1991). Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. The American Journal of Cardiology, 67, 774-776.
17. National Institute for Clinical Excellence. (2002). Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and second care. http://www.nice.org.uk/pdf/ cgINICEguidelineoster.pdf.
18. O'Halloran, R.L., & Frank, J.G. (2000). Asphyxial death during prone restraint revisited: a report of 21 cases. The American Journal of Forensic Medicine and Pathology, 21, 39-52.
19. Pilowsky, L.S., Ring, H., Shine, P.J., e.a. (1992). Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. The British Journal of Psychiatry, 160, 831-835.
20. Reilly, J.G., Ayis, S.A., Fetrier, I.N., e.a. (2000). QTC-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048-1052.
21. Taylor, D., Paton, C., & Kerwin, R. (2003). Guidelines for the use of Clopixol Acuphase (zuclopenthixol acutate). In D. Taylor, C. Paton & R. Kerwin, The Maudsley Prescribing Guidelines 2003 (pp. 240). London: Martin Dunitz Taylor & Francis Group.
22. Werkgroep Schizofrenie. (2005). Multidisciplinaire Richtlijn Schizofrenie. Utrecht: Trimbos-instituut.
23. World Health Organization. (2001). Pharmaceuticals: restrictions in use and availability. http://whqlibdoc.who.int/hq/2003/ EDM_QSM_2003.5.pdf